Contineum Therapeutics Announces 2025 Annual Meeting Voting Results

Contineum Therapeutics (Nasdaq: CTNM) filed a routine Form 8-K reporting the voting outcomes of its 2025 virtual Annual Meeting held on June 26, 2025.

Rhea-AI Filing Summary

Contineum Therapeutics (Nasdaq: CTNM) filed a routine Form 8-K reporting the voting outcomes of its 2025 virtual Annual Meeting held on June 26, 2025.

Shareholders re-elected Class I directors Sarah Boyce, Troy Ignelzi and Olivia Ware, and ratified Ernst & Young LLP as independent auditor for fiscal 2025. No additional proposals or material events were disclosed.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the results of Contineum Therapeutics' 2025 director elections (CTNM)?

Shareholders elected Sarah Boyce (12,698,010 for), Troy Ignelzi (13,227,301 for), and Olivia Ware (12,756,245 for); each will serve until the 2028 meeting.

How many shares were entitled to vote at CTNM's 2025 Annual Meeting?

A total of 19,142,377 Class A shares were outstanding and entitled to vote as of April 28, 2025.

Was Ernst & Young LLP ratified as CTNM's independent auditor for 2025?

Yes. The appointment was ratified with 15,331,748 votes for, 53,939 against and 4,562 abstentions.

When did CTNM hold its 2025 Annual Meeting of Stockholders?

The virtual Annual Meeting took place on June 26, 2025.

How many broker non-votes were recorded in the 2025 director elections for CTNM?

2,050,305 broker non-votes were recorded for each director nominee.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 04:07 PM Learn about SEC filing dates

false 0001855175 0001855175 2025-06-26 2025-06-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

Contineum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42001		27-1467257
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3565 General Atomics Court, Suite 200 San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

(858) 333-5280

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share		CTNM		The Nasdaq Global Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company          ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 26, 2025, Contineum Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 28, 2025, the record date for the Annual Meeting, there were 19,142,377 shares of Class A common stock outstanding and entitled to vote at the Annual Meeting. The Annual Meeting was conducted virtually, and the following is a brief summary of the matters voted upon by stockholders at the Annual Meeting.

Proposal 1: Election of Directors

The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2028 Annual Meeting of Stockholders or until their respective successors have been elected or appointed. The final voting results are as follows: 

Director Nominee		Votes For		Votes Withheld		Broker Non-Votes
Sarah Boyce		12,698,010		641,934		2,050,305
Troy Ignelzi		13,227,301		112,643		2,050,305
Olivia Ware		12,756,245		583,699		2,050,305

Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
15,331,748		53,939		4,562		N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 26, 2025

Contineum Therapeutics, Inc.
By:		/s/ Peter Slover
		Peter Slover
		Chief Financial Officer Principal Financial Officer and Principal Accounting Officer